Inventor · disambiguated record
Bum-Chan Park
Also filed as: PARK BUM-CHAN
12 granted patents·8 pending applications·7 citations·filing 2013–2023
83Inventor score
Files withY BIOLOGICS INC12HK INNO N CORP2ANTIBODY AND RECEPTOR THERAPEUTICS CO LTD1LEGOCHEM BIOSCIENCES INC1METABOLIC ENG LABORATORIES CO LTD1
Top patents by PatentIndex Score
20 records- 0186US10640576B2Cell engaging binding moleculesY BIOLOGICS INC·Filed 2019·Granted May 5, 2020·3 cites·30 claims
- 0281US10836833B2Cell engaging binding moleculesY BIOLOGICS INC·Filed 2020·Granted Nov 17, 2020·1 cites·17 claims
- 0373US11306141B2Antibody against human DLK1 and use thereofY BIOLOGICS INC·Filed 2018·Granted Apr 19, 2022·1 cites·17 claims
- 0470US11248048B2Antibody to programmed cell death 1 (PD-1) and use thereofY BIOLOGICS INC·Filed 2017·Granted Feb 15, 2022·1 cites·12 claims
- 0566US10654944B2Cell engaging binding moleculesY BIOLOGICS INC·Filed 2019·Granted May 19, 2020·0 cites·14 claims
- 0666US10633458B2Cell engaging binding moleculesY BIOLOGICS INC·Filed 2019·Granted Apr 28, 2020·0 cites·19 claims
- 0765US2025186495A1Pd-l1-specific chimeric antigen receptor and immune cell comprising sameVAXCELL BIO CO LTD·Filed 2023·Application pending·0 cites
- 0859US9388223B2Myostatin inhibitor comprising extracellular water-soluble domains of DLK1 as active ingredientANTIBODY AND RECEPTOR THERAPEUTICS CO LTD·Filed 2013·Granted Jul 12, 2016·1 cites·11 claims
- 0958US2025019430A1Resistin-specific antibody and use thereofSEOUL NAT UNIV HOSPITAL·Filed 2022·Application pending·0 cites
- 1057US2024158503A1Anti-vsig4 antibody or antigen binding fragment and uses thereofPF MEDICAMENT·Filed 2022·Application pending·0 cites
- 1157US2025297013A1Hla-g-specific antibody and use thereofHK INNO N CORP·Filed 2023·Application pending·0 cites
- 1254US11945864B2Monoclonal antibody specifically binding to LAG-3 and use thereofY BIOLOGICS INC·Filed 2019·Granted Apr 2, 2024·0 cites·16 claims
- 1352US2022306736A1Anti-vsig4 antibody or antigen binding fragment and uses thereofY BIOLOGICS INC·Filed 2020·Application pending·0 cites
- 1448US2022339291A1Antibody-drug conjugates that target dlk1 and uses thereofLEGOCHEM BIOSCIENCES INC·Filed 2020·Application pending·0 cites
- 1547US12139530B2Bispecific antibody specifically binding to IL-17A and TNF-αY BIOLOGICS INC·Filed 2020·Granted Nov 12, 2024·0 cites·21 claims
- 1645US2024270859A1ANTI-OX40L ANTIBODY, ANTI-OX40L/ANTI-TNFa BISPECIFIC ANTIBODY, AND USES THEREOFHK INNO N CORP·Filed 2020·Application pending·0 cites
- 1739US10448662B2Composition for preventing or treating fatty liver or insulin resistance syndrome including extracellular domain of delta-like 1 homologY BIOLOGICS INC·Filed 2016·Granted Oct 22, 2019·0 cites·1 claims
- 1839US2019389973A1Novel multi-specific binding proteinsY BIOLOGICS INC·Filed 2017·Application pending·0 cites
- 1937US10919966B2Antibody to programmed death-ligand 1 (PD-L1) and use thereofY BIOLOGICS INC·Filed 2017·Granted Feb 16, 2021·0 cites·10 claims
- 2036US10087248B2Anti-TNF-α/CXCL10 double-targeting antibody and use thereofMETABOLIC ENG LABORATORIES CO LTD·Filed 2014·Granted Oct 2, 2018·0 cites·13 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →